2023
Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer
Otegui N, Houry M, Arozarena I, Serrano D, Redin E, Exposito F, Leon S, Valencia K, Montuenga L, Calvo A. Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer. Cancers 2023, 15: 3076. PMID: 37370686, PMCID: PMC10295869, DOI: 10.3390/cancers15123076.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsLung cancer patientsSmall cell lung cancerCancer patientsTumor microenvironmentLung cancerEffects of ICIsEfficacy of ICIsChimeric antigen receptor cellsCell lung cancer patientsCytotoxic T cellsImmunosuppressive tumor microenvironmentCell-extrinsic mechanismsCell-intrinsic alterationsGreat clinical successLack of responseCheckpoint inhibitorsICI responseTherapeutic responseT cellsDNA damage repair pathwaysClinical successImmunotherapyMetabolic alterationsTherapeutic interventions
2021
Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies
Palanca-Ballester C, Rodriguez-Casanova A, Torres S, Calabuig-Fariñas S, Exposito F, Serrano D, Redin E, Valencia K, Jantus-Lewintre E, Diaz-Lagares A, Montuenga L, Sandoval J, Calvo A. Cancer Epigenetic Biomarkers in Liquid Biopsy for High Incidence Malignancies. Cancers 2021, 13: 3016. PMID: 34208598, PMCID: PMC8233712, DOI: 10.3390/cancers13123016.Peer-Reviewed Original ResearchLiquid biopsyEpigenetic biomarkersSpecific epigenetic alterationsDNA methylation changesTumor microenvironmentDNA promoter methylationCommon clinical practiceHigh-incidence malignancyActionable genetic alterationsCancer drug responseSingle geneEpigenetic eventsDNA methylationGene setsMethylation changesTypes of cancerEpigenetic alterationsPrimary tumorClinical trialsClinical valueCerebrospinal fluidHigh incidenceTissue biopsiesClinical practiceEarly alterations